# A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML

> **NCT05199051** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Centre Antoine Lacassagne** · enrollment: 19 (actual)

## Conditions studied

- AML
- Leukaemia (Acute Myeloid)

## Interventions

- **COMBINATION_PRODUCT:** Gemtuzumab ozogamicine - Cytarabine - Gilteritinib

## Key facts

- **NCT ID:** NCT05199051
- **Lead sponsor:** Centre Antoine Lacassagne
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-06-03
- **Primary completion:** 2028-07-10
- **Final completion:** 2028-07-10
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2026-01-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05199051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05199051, "A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD and/or FLT3-TKD Relapse/Refractory (R/R) AML". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05199051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*